To amend title III of the Public Health Service Act to terminate the effective time period for immunity for manufacturers of COVID-19 vaccines, and for other purposes.

Bill 117 hr 6106 aims to amend title III of the Public Health Service Act in order to end the immunity granted to manufacturers of COVID-19 vaccines. This immunity, which protects vaccine manufacturers from liability for any potential harm caused by their vaccines, has been a topic of debate and concern among the public.

The bill seeks to terminate this immunity, which has been in place to encourage the rapid development and distribution of COVID-19 vaccines. By removing this immunity, manufacturers would be held accountable for any adverse effects or harm caused by their vaccines.

In addition to ending the immunity for vaccine manufacturers, the bill also includes provisions for other purposes related to public health and safety. The specifics of these provisions are not detailed in the summary, but they are likely to address various aspects of the COVID-19 pandemic and its impact on the population. Overall, Bill 117 hr 6106 is a significant piece of legislation that could have far-reaching implications for the vaccine industry and public health. It will be important to closely monitor the progress of this bill and its potential impact on the ongoing efforts to combat the COVID-19 pandemic.